Two Generations of Incretin Therapy
Semaglutide and tirzepatide represent the current frontline of incretin-based metabolic therapy, yet they differ in a fundamental way. Semaglutide is a selective GLP-1 receptor agonist, while tirzepatide is a dual GIP/GLP-1 receptor agonist — the first approved molecule to target both incretin pathways simultaneously. This dual mechanism has significant implications for efficacy, tolerability, and the breadth of metabolic benefits each agent delivers.
Semaglutide, marketed as Ozempic and Wegovy, has been extensively studied in the SUSTAIN and STEP trial programmes. At the highest approved dose of 2.4 mg weekly, the STEP trials demonstrated mean weight loss of approximately 15–17% over 68 weeks. Tirzepatide, marketed as Mounjaro, showed even greater weight reduction in the SURMOUNT trials — up to 22.5% at the 15 mg dose — making it the most effective anti-obesity medication studied to date in randomised controlled trials.
Efficacy and Tolerability Differences
The dual agonism of tirzepatide appears to confer additive metabolic benefits. Glucose-dependent insulinotropic polypeptide (GIP) receptor activation enhances fat oxidation and may improve lipid metabolism beyond what GLP-1 alone achieves. Head-to-head data from the SURPASS-2 trial showed tirzepatide achieved superior HbA1c reductions compared to semaglutide 1 mg across all doses tested.
Both agents share a similar gastrointestinal side-effect profile — nausea, vomiting, and diarrhoea are the most commonly reported adverse events, typically occurring during dose titration and improving over time. Slow, structured dose escalation is critical for minimising these effects. At DOSIST, our clinicians follow evidence-based titration schedules tailored to individual tolerance, ensuring patients achieve therapeutic doses with minimal discomfort.
Choosing the Right Therapy
The choice between semaglutide and tirzepatide depends on individual clinical factors: baseline weight, glycaemic status, cardiovascular risk profile, and patient preference regarding injection frequency. Both are administered subcutaneously once weekly. Patients with significant insulin resistance or those seeking maximal weight reduction may benefit more from tirzepatide's dual mechanism, while semaglutide has a longer track record and more extensive cardiovascular outcome data.
- Semaglutide: selective GLP-1 RA, ~15–17% mean weight loss, robust cardiovascular data
- Tirzepatide: dual GIP/GLP-1 RA, ~20–22.5% mean weight loss, superior glycaemic control
- Both require structured dose titration to manage GI side effects
- Medical supervision is essential for safe prescribing and monitoring
